Actively Recruiting

Phase 4
Age: 45Years +
All Genders
NCT07168421

LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery

Led by Insel Gruppe AG, University Hospital Bern · Updated on 2026-05-05

114

Participants Needed

1

Research Sites

96 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Limiting perioperative tachycardia (aiming for a heart rate \<90 beats per minute throughout the perioperative period) using the ultra-short acting beta-blocker landiolol in patients with cardiovascular risk factors undergoing major surgery might lower the incidence of perioperative myocardial injury. Feasibility of the intervention needs to be proven prior to conduction of a larger trial.

CONDITIONS

Official Title

LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery

Who Can Participate

Age: 45Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients undergoing elective non-cardiac surgery defined as intermediate or high-risk by the 2022 European Society of Cardiology guidelines
  • Surgery performed under general anesthesia
  • Expected length of hospital stay at least 24 hours
  • Age 45 years or older
  • At least two of the following risk factors: age 75 years or older, arterial hypertension, ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease, peripheral artery disease, diabetes mellitus, GFR 59 ml/min/1.73 m2 or lower, pre-operative NTproBNP over 200 pg/ml
  • Evidence of excessive sympathetic outflow proven by exercise testing, shown as impaired heart rate recovery (12 bpm or less within 1 minute after exercise) or exaggerated heart rate response (12 bpm or more after 3 minutes of unloaded pedaling)
Not Eligible

You will not qualify if you...

  • Unable to consent or follow study procedures
  • Absolute contraindications for exercise testing
  • Pregnancy or intention to become pregnant
  • Active cardiac conditions such as unstable coronary syndromes, decompensated heart failure, significant arrhythmias, or severe valvular disease
  • Urgent or emergency surgery
  • Use of beta-blockers within 30 days prior to recruitment
  • Contraindications for beta-blocker therapy including bradycardia (heart rate less than 55 bpm), hypotension (systolic blood pressure less than 100 mmHg), severe peripheral vascular disease, severe asthma, allergy, or higher-degree atrioventricular block
  • Severe preoperative anemia (hemoglobin less than 100 g/L) without a plan for correction before surgery
  • Planned intermediate care or intensive care admission
  • Prior enrollment in this trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Bern University Hospital, Freiburgstrasse

Bern, Switzerland, 3010

Actively Recruiting

Loading map...

Research Team

C

Christian M Beilstein, MD

CONTACT

P

Patrick Y Wuethrich, Prof MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery | DecenTrialz